Company intelligence / Profile preview

APIRx Pharmaceutical USA

Reno, NV, USA

Ownership: Private
Employees: ~25
Development stage: Other

Overview

APIRx Pharmaceuticals is a clinical-stage biotechnology company specializing in the development of cannabinoid-based pharmaceutical products. The company holds an extensive intellectual property portfolio covering various delivery technologies, including functional chewing gums, topical creams, and ophthalmic formulations. Its clinical pipeline targets a broad range of indications such as chronic pain, dementia, restless leg syndrome, and gastrointestinal disorders. In August 2022, APIRx was acquired by Incannex Healthcare, creating a leading global entity in the medicinal cannabis and psychedelic medicine sectors.

Therapeutic areas: NeurologyDermatologyGastroenterologyPsychiatryOncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on APIRx Pharmaceutical USA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APIRx Pharmaceutical USA.

Explore the full profile